Taysha Gene Shares Soar 8.02% on FDA Milestone

Taysha Gene(TSHA) shares surged 8.02% today, marking the sixth consecutive day of gains, with a cumulative increase of 34.74% over the past six days. The stock price reached its highest level since December 2024, with an intraday gain of 16.88%.

The strategy of buying TSHA shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years, with a 23.40% increase, slightly underperforming the S&P 500's 46.67% return over the same period. However, it's important to note that this strategy involved significant volatility, with a 38.4% peak-to-trough decline at its worst, highlighting the need for careful consideration of risk and market conditions.

Taysha Gene Therapies has recently achieved a significant regulatory milestone with the FDA providing written alignment on key elements of the TSHA-102 pivotal Part B trial design for Rett syndrome. This progress is crucial for advancing clinical trials and could positively influence investor confidence.

In the first quarter of 2025, Taysha Gene Therapies reported a loss of $0.08 per share, in line with the consensus estimate, and revenues of $2.3 million, surpassing expectations. The company has shown resilience by outperforming consensus estimates in recent quarters, which may contribute to positive market sentiment.

Analyst Gil Blum from Needham has reiterated a Buy rating on Taysha Gene Therapies, maintaining a price target of $6.00, which suggests a positive outlook from financial analysts.